<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies demonstrated that interleukin-12 (IL-12) enhances the non-MHC-restricted cytotoxic activity of NK cells and facilitate specific allogeneic human cytotoxic T lymphocyte responses against fresh <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells and cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e> gene, WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi>, has been used as a marker of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) for evaluating therapeutic efficacy of patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>This study was aimed to investigate whether in vitro IL-12 can lower WT1 gene expression in peripheral blood monuclear cells (PBMNC) from patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>PBMNC from these 30 patients and 5 healthy volunteers were cultured at 5 x 10(5) cells/ml alone with or without 100 units/ml of IL-12 for 3 days </plain></SENT>
<SENT sid="4" pm="."><plain>WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> was measured by competitive reverse transcription polymerase chain reaction (RT-PCR) since WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> is considered as a marker of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) in <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The results demonstrated that WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in PBMNC of 5 healthy volunteers was less than 10(3) copies/microg of total <z:chebi fb="40" ids="33697">RNA</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Following the 3-day IL-12 treatment, mean WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> of PBMNC was reduced from 10(4.8) to 10(4.2) copies/microg of total <z:chebi fb="40" ids="33697">RNA</z:chebi> in 6 <z:mp ids='MP_0005481'>CML</z:mp> patients, from 10(5.4) to 10(4.8) copies/microg in 12 MDS patients and from 10(5.0) to 10(4.2) copies/microg in 5 AML patients in CR, but not reduced in 5 of 7 AML in non-CR </plain></SENT>
<SENT sid="7" pm="."><plain>It is concluded that IL-12 significantly decrease the quantity of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells in PBMNC of most patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:mp ids='MP_0005481'>CML</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in CR </plain></SENT>
<SENT sid="8" pm="."><plain>IL-12 may be of considerable benefit in the elimination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>